Here is a quick breakdown of where the key next-generation candidates currently stand: Retatrutide (Eli Lilly): Phase 3 trials are actively studying cardiovascular outcomes alongside weight loss
This signals a shift in thinking unlike anything weve seen in a generation a move toward treating obesity first, rather than waiting for people to develop the many complications that follow, Arrone said
10.1165/rcmb.2023-0038OC 37 YanqingL.ZhangC.ChengH.LvL.ZhuX.MaM.et al (2024)
Primary care clinics are overwhelmed with patient portal messages, so its important to understand what kinds of follow-up appointments youll need, and how to escalate concerns. With no non-GLP-1 options available through Bridge, those who cant tolerate any of the covered medications should talk with their prescriber about non-GLP-1 options that they could potentially pay for out of pocket
Age and Overall Health: Younger, healthier patients typically recover faster
Always practice moderation
